Roche: signs technology licensing deal with Amunix
(CercleFinance.com) - US biopharmaceutical firm Amunix said on Friday that it has signed a deal to provide a technology license that will help the Swiss drugmaker discover and develop non-oncology therapeutics.
The Mountain View, California-based company said it will receive a 40 million dollar upfront payment under the terms of the deal.
The firm may also receive up to 1.5 billion dollars in payments, depending on the achievement of certain developmental and sales milestones, plus royalties on sales of commercialized products.
Amunix uses precision protein engineering to enable T cell engagers and cytokines to treat patients with solid tumors.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
The Mountain View, California-based company said it will receive a 40 million dollar upfront payment under the terms of the deal.
The firm may also receive up to 1.5 billion dollars in payments, depending on the achievement of certain developmental and sales milestones, plus royalties on sales of commercialized products.
Amunix uses precision protein engineering to enable T cell engagers and cytokines to treat patients with solid tumors.
Copyright (c) 2020 CercleFinance.com. All rights reserved.